The Low DoseThe GLP-1 price desk
Programme

Hims & Hers tirzepatide review

Advertised at $199, billed at $238. Position 8 of 18 on our board.

Updated 2026-09-18

DISCLOSURE — Coreage Rx pays this desk a commission when a reader signs up through our link. It buys no ranking, no score and no deletions. Method: how we rate. Full terms: disclosure.

Hims & Hers advertises compounded tirzepatide at $199. The number that hits your card is $238.

The difference is the $39 membership, billed alongside the medication rather than inside it. Not hidden — but not in the headline either, and it is the figure that decides your annual total. Branded Zepbound through the same account is $1,899 a month.

The numbers

Hims & Hers · tirzepatide
Advertised$199/mo
Membership$39/mo
Billed$238/mo
Advertised-to-billed gap+$39/mo
Per year$2,856
Board position8 of 18, cheapest first

The $199 compounded injection price sits on top of the membership. Branded Zepbound through the same platform is $1,899/month.

Where the gap is

$39 a month, every month, on top of whatever medication tier you land in. That is $468 a year for the platform. The other gap worth flagging: the $79 figure in Hims advertising refers to oral kits, not the weekly injection.

Against the board

$238 all in puts Hims mid-board — above Coreage Rx at $199 and Zealthy at $216, below Mochi at $278 and everything at $399 and up.

ProgrammeAdvertisedBilledGapVs board floor
Coreage Rx$149$199+$50+$74/mo
Trimi$125$125none
Ozari Health$125$125none
Fifty 410$133$133none+$8/mo
PlexusDx$129$189+$60+$64/mo
Ivím Health$199$199none+$74/mo
Zealthy$216$216none+$91/mo
Hims & Hers$199$238+$39+$113/mo

How the programme works

Large publicly traded telehealth platform. Sells oral kits, compounded injections and branded Zepbound side by side, with a membership required across the board.

Verified facts

  • Weight-loss membership advertised at $39 for the first month.
  • Compounded GLP-1 injections priced from $199/month.
  • Oral medication kits priced from $79/month.
  • Branded Zepbound offered at $1,899/month.
  • Company has announced oral semaglutide pricing starting around $49/month, with the 1.5 mg dose around $149/month.

Checked 2026-09-18. This market re-prices without notice — anything older than a month is a starting point, not a quote.

For it

  • One account covers oral, compounded injectable and branded options.
  • Large enough to keep supply steady when smaller sellers run dry.
  • Branded Zepbound is available without leaving the platform.

Against it

  • The $39 membership is charged on top of every medication price.
  • The cheapest advertised numbers refer to oral kits, which are not equivalent to weekly injections.
  • Renewal pricing is materially higher than the introductory rate.

Read this bit. The advertised entry prices and the membership are separate charges. Add $39/month to whatever medication figure you were quoted.

Score

3.5 out of 5 on our rubric, which is fixed before assessment and published on how we rate.

CriterionWeightScore
True monthly cost30%3.4 / 5
Price honesty20%3.2 / 5
Clinical support20%3.6 / 5
Pharmacy sourcing15%3.9 / 5
Cancelling15%3.3 / 5

Verdict

Fairly priced for what it is, provided you do the addition. Big, reliable, and the only account here that runs from an oral kit to branded Zepbound without starting over.

More from the desk

  • Coreage Rx tirzepatide review

    Advertised at $149, billed at $199. Position 1 of 18 on our board.

  • Trimi tirzepatide review

    Advertised at $125 and billed at $125 — no gap. Position 2 of 18 on our board.

  • Ozari Health tirzepatide review

    Advertised at $125 and billed at $125 — no gap. Position 3 of 18 on our board.

  • Cheapest right now

    Every programme sorted on what it bills, not what it advertises. Floor: $199/mo tirzepatide, $149/mo semaglutide.

  • Six fee traps

    Every advertised-to-billed gap on our board comes from one of these six structures. Learn them and you can read any of these sites in ninety seconds.

  • Where the traps are

    The biggest advertised-to-billed gaps on our board, and the programmes charging most for the same category of medication.